GlassScriptPhysician profile
Lisellet Morin
NPI 1053615237
$2,591.66
in general payments reported to CMS, 2019-2025
24 companies · $712 in 2025
The $712 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $290 · 2022: $17.83 · 2023: $490 · 2024: $1,082 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,033 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,033.18 |
| Education | $250.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $362.89 | 2023-2025 | |
| Incyte Corporation | $324.44 | 2021-2024 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $276.24 | 2024-2025 | Enhertu |
| Lilly USA, LLC | $264.46 | 2023-2025 | Verzenio |
| E.R. Squibb & Sons, L.L.C. | $179.65 | 2021 | |
| Astellas Pharma US INC | $159.98 | 2023 | |
| Daiichi Sankyo INC. | $159.00 | 2024-2025 | Enhertu, Injectafer |
| Merck Sharp & Dohme LLC | $151.62 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $118.35 | 2021-2025 | |
| Sobi, INC | $88.16 | 2024 | |
| Amgen INC. | $73.99 | 2021 | |
| Pharmaessentia USA Corporation | $65.04 | 2024 | Besremi |
| Pharmacosmos Therapeutics INC. | $62.60 | 2024-2025 | Monoferric |
| Genzyme Corporation | $52.53 | 2023 | |
| Agios Pharmaceuticals, INC. | $42.03 | 2024 | Pyrukynd |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $34.24 | 2025 | |
| Janssen Biotech, INC. | $27.78 | 2024 | Erleada, Rybrevant, Akeega |
| Caris Mpi, INC. | $25.00 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $24.80 | 2024 | Orserdu |
| Kedrion Biopharma, INC. | $22.61 | 2024 | Kedrab, Koate, Gammaked |
| Alexion Pharmaceuticals, INC. | $20.67 | 2023 | |
| Janssen Pharmaceuticals, INC | $18.83 | 2024 | Xarelto |
| Puma Biotechnology, INC. | $18.45 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $18.30 | 2024 | Somatuline Depot, Onivyde |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisellet Morin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.